Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer q.

Business Wire • Oct 15, 2026

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.

Zacks Investment Research • Sep 22, 2026

Think Outside the Box With These 3 Companies That Make Unusual Business Models Work

Some of the most successful companies started with business models that likely seemed unusual at first. Investors willing to take a chance on what may appear to be a quirky approach could find a surprisingly strong set of financials and a compelling case for future growth.

MarketBeat • Sep 21, 2026

Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 31, 2026

Fulgent Genetics Q2 Earnings Call Highlights

Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.

MarketBeat • Jul 30, 2026

Fulgent Reports Second Quarter 2026 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Results: Revenue of $85.4 million GAAP loss of $29.5 million, or $(1.05) per share Non-GAAP loss of $16.2 million, or $(0.58) per share Adjusted EBITDA loss of $17.1 million Non.

Business Wire • Jul 30, 2026

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to earnings of $0.07 per share a year ago.

Zacks Investment Research • Jul 30, 2026

Fulgent Genetics: Strong Moves By Management Keep Me Bullish

Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Recent opportunistic share repurchases at $15.42/share and insider buying highlight management's conviction in FLGT's intrinsic value. FLGT trades below tangible book value, with net assets per share estimated at $24.09–$29, offering a margin of safety.

Seeking Alpha • Jul 13, 2026

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer que.

Business Wire • Jul 9, 2026

Fulgent Presents Updated FID-007 Data at ASCO 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled “FID.

Business Wire • Jun 1, 2026